Rahul N Khurana1, Carol Hoang2, Arshad M Khanani3, Nikolai Steklov4, Lawrence J Singerman5. 1. Northern California Retina Vitreous Associates, Mountain View, CA; University of California, San Francisco, San Francisco, CA. Electronic address: rnkhurana@gmail.com. 2. Clearside Biomedical, Alpharetta, GA. 3. Sierra Eye Associates, Reno, NV; University of Nevada, Reno School of Medicine, Reno, NV. 4. doc.ai, San Francisco, CA. 5. Retina Associates of Cleveland, Cleveland, OH; Case Western Reserve University, Cleveland, OH; Bascom Palmer Eye Institute, Miami, FL.
Abstract
PURPOSE: To determine if a mobile application, Checkup Vision Assessment System (Checkup; Verana Health, San Francisco, CA), can reliably monitor visual acuity (VA) and metamorphopsia remotely vs standard VA reference tests in the clinic. With the current COVID-19 pandemic, an even greater need for remote monitoring exists. Mobile tools enhance ability to monitor patients virtually by enabling remote monitoring of VA and Amsler grid findings. DESIGN: Prospective, multicenter reliability analysis PARTICIPANTS: : Patients (N=108) with near corrected VA better than 20/200 and a diagnosis of age-related macular degeneration, diabetic retinopathy or healthy patients without retinal disease (best corrected visual acuity [BCVA] 20/32 or better). INTERVENTION: Participants were tested with Checkup and reference VA and Amsler tests, with the order of testing (Checkup or reference) randomized. Patients monitored their vision using Checkup at least twice a week at home between office visits. MAIN OUTCOME MEASURES: Near corrected VA, Amsler grid test results. RESULTS: Agreement was strong between Checkup and reference tests for VA (r=0.86) and Amsler (sensitivity 93%, specificity 92%). Home vs clinic testing showed excellent agreement (r=0.96). Patients reported successful home use. There were no serious adverse events or discontinuations. Patients rated the usability of Checkup to be excellent. CONCLUSIONS: There was good agreement between Checkup and in-clinic tests for VA and Amsler grid. The low variance of Checkup testing, agreement between in-clinic and home results, and excellent usability, support Checkup as a reliable method for monitoring retinal pathology in clinic and home settings.
PURPOSE: To determine if a mobile application, Checkup Vision Assessment System (Checkup; Verana Health, San Francisco, CA), can reliably monitor visual acuity (VA) and metamorphopsia remotely vs standard VA reference tests in the clinic. With the current COVID-19 pandemic, an even greater need for remote monitoring exists. Mobile tools enhance ability to monitor patients virtually by enabling remote monitoring of VA and Amsler grid findings. DESIGN: Prospective, multicenter reliability analysis PARTICIPANTS: : Patients (N=108) with near corrected VA better than 20/200 and a diagnosis of age-related macular degeneration, diabetic retinopathy or healthy patients without retinal disease (best corrected visual acuity [BCVA] 20/32 or better). INTERVENTION: Participants were tested with Checkup and reference VA and Amsler tests, with the order of testing (Checkup or reference) randomized. Patients monitored their vision using Checkup at least twice a week at home between office visits. MAIN OUTCOME MEASURES: Near corrected VA, Amsler grid test results. RESULTS: Agreement was strong between Checkup and reference tests for VA (r=0.86) and Amsler (sensitivity 93%, specificity 92%). Home vs clinic testing showed excellent agreement (r=0.96). Patients reported successful home use. There were no serious adverse events or discontinuations. Patients rated the usability of Checkup to be excellent. CONCLUSIONS: There was good agreement between Checkup and in-clinic tests for VA and Amsler grid. The low variance of Checkup testing, agreement between in-clinic and home results, and excellent usability, support Checkup as a reliable method for monitoring retinal pathology in clinic and home settings.